CDMOs offering Ophthalmic Manufacturing with Small Molecule
8 published
8 published CDMOs match Ophthalmic Manufacturing and Small Molecule.
Locations in this set include United States, India, France, Germany, United Kingdom, and Canada.
Capabilities that show up most often in this set: CMC Analytical Development, Formulation Development, Process Development, Sterile Fill-Finish & Aseptic Manufacturing, and Technology Transfer.
Matching companies
- AbbVie Contract ManufacturingGlobal CMO offering small and large molecule drug substance to drug product manufacturing, with specialized capabilities in antibody drug conjugates, aseptic fill-finish, biologics (mAbs), HPAPI, and eye care across 12 facilities in the US and Europe.
Akums Drugs and Pharmaceuticals Ltd.India's largest CDMO with 15+ state-of-the-art facilities and 30% domestic market share, manufacturing 4,100+ formulations across tablets, capsules, injectables, APIs, and specialty dosage forms under WHO-GMP, USFDA, EU-GMP, and TGA compliance.- Burrard PharmaceuticalsVancouver-based CDMO delivering technology transfer, formulation development, and GMP manufacturing for 75+ molecules across oncology, diabetes, and respiratory therapeutics since 2005.
Gland Pharma LimitedGland Pharma is a vertically integrated CDMO offering sterile injectable manufacturing across vials, lyophilized, prefilled syringes, and ophthalmic formats, with four cGMP-compliant formulation facilities and four API manufacturing units, supported by R&D capabilities in formulation, analytical, and process development.
MedpharmSpecialized CDMO for topical, transdermal, and transepithelial drug products offering formulation development, analytical testing, process scale-up, and GMP manufacturing from early development through commercialization.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Siegfried HoldingGlobal CDMO with 16 production sites across four continents, offering integrated development and manufacturing from early-phase to commercial scale for drug substance and drug product.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/ophthalmic-manufacturing/small-molecule.md